David Drutz - 23 Mar 2023 Form 4 Insider Report for Altimmune, Inc. (ALT)

Role
Director
Signature
/s/ Richard Eisenstadt, as Attorney-in-Fact
Issuer symbol
ALT
Transactions as of
23 Mar 2023
Net transactions value
+$38,430
Form type
4
Filing time
27 Mar 2023, 17:17:23 UTC
Previous filing
21 Nov 2022
Next filing
15 Aug 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ALT Common Stock, par value $0.0001 Purchase $38,430 +9,000 +44% $4.27 29,484 23 Mar 2023 See Footnote F1, F2, F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents Common Stock purchased and immediately transferred to Pacific Biopharma Associates, LLC.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.265 to $4.28, inclusive. The reporting person undertakes to provide to Altimmune, Inc., any security holder of Altimmune, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
F3 Includes 20,151 shares of Common Stock previously owned directly by the reporting person which were transferred to Pacific Biopharma Associates, LLC.
F4 Represents Common Stock held by Pacific Biopharma Associates, LLC, of which the reporting person is the President.